Hexvix/Cysview (hexaminolevulinate)
Diagnosis of Non-Muscle-Invasive Bladder Cancer (NMIBC)
ApprovedCommercial; Ongoing health economic and outcomes research
Key Facts
Indication
Diagnosis of Non-Muscle-Invasive Bladder Cancer (NMIBC)
Phase
Approved
Status
Commercial; Ongoing health economic and outcomes research
Company
About Photocure
Photocure ASA, 'The Bladder Cancer Company,' is a commercial-stage biopharmaceutical firm dedicated to improving the diagnosis and management of bladder cancer through its photodynamic technology platform. Its approved product, Hexvix, enhances the accuracy of cystoscopy procedures, leading to better patient outcomes and reduced recurrence rates. The company is actively pursuing partnerships, AI integration, and new clinical data to solidify its position as a leader in urologic oncology diagnostics while maintaining a strong commitment to ESG principles.
View full company profile